Need assistance?
Aug 25 2026
Data From Alkermes’ Positive Study in Adults with Narcolepsy Type 1
Just announced from Alkermes: The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
DUBLIN–(BUSINESS WIRE)–Aug. 24, 2026– Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology.
Read the full release
Advertisement
